Results 21 to 30 of about 13,086 (214)

HMGB1 Carried by Small Extracellular Vesicles Potentially Plays a Role in Promoting Acquired Middle Ear Cholesteatoma

Diagnostics, 2023
Cholesteatoma is a specific medical condition involving the abnormal, non-cancerous growth of skin-like tissue in the middle ear, potentially leading to a collection of debris and even infections. The receptor for advanced glycation (RAGE) and its ligand,
Michał W. Łuczak, Karolina Dżaman, Łukasz Zaręba, Katarzyna Czerwaty, Jacek Siewiera, Alicja Głuszko, Ewa Olszewska, Jacek Brzost, Ireneusz Kantor, Mirosław J. Szczepański, Nils Ludwig   +10 more
doaj   +1 more source

Immunohistochemical localization of d‐β‐aspartic acid in congenital and acquired middle ear cholesteatoma

Laryngoscope Investigative Otolaryngology, 2022
Objective/Hypothesis Middle ear cholesteatoma is characterized by abnormal growth of the keratinizing squamous epithelium of the temporal bone. d‐β‐aspartic acid is the major isomer of d‐aspartic acid found in elderly tissue.
Shiori Kitaya, Ryoukichi Ikeda, Jun Suzuki, Hidetoshi Oshima, Yuri Nomura, Yusuke Kusano, Nobuo Ohta, Tetsuaki Kawase, Kazue Ise, Kazuhiro Murakami, Yasuhiro Nakamura, Hironobu Sasano, Yukio Katori   +12 more
doaj   +1 more source

Epidermal Growth Factor Expression in Middle Ear Cholesteatoma

Kaohsiung Journal of Medical Sciences, 2004
Middle ear cholesteatoma is destructive to auditory ossicles and temporal bone, and treatment usually requires surgical removal of all epithelial content.
Hung-Pin Chi, Kuen-Yao Ho, Chih-Feng Ta, Ling-Feng Wang, Ka-Wo Lee, Wen-Rei Kuo   +5 more
doaj   +1 more source

Childhood cholesteatoma

European Annals of Otorhinolaryngology, Head and Neck Diseases, 2010
Although cholesteatoma was first described in 1683, its etiopathogeny remains unexplained. In children, there are two forms: acquired cholesteatoma, resembling the adult form, and congenital cholesteatoma. The acquired form has become less frequent in recent years, thanks to progress in the treatment of childhood otitic pathology.
Nevoux, J., Lenoir, M., Roger, G., Denoyelle, F., Ducou Le Pointe, H., Garabédian, E.-N.   +5 more
openaire   +2 more sources

Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives [PDF]

Clinical and Experimental Otorhinolaryngology, 2016
Cholesteatoma is a cystic non tumorous lesion of the temporal bone that has the ability to destroy nearby structures by its power to cause bone resorption and as a result, fatal complications prevail.
Mahmood A. Hamed, Seiichi Nakata, Ramadan H. Sayed, Hiromi Ueda, Badawy S. Badawy, Yoichi Nishimura, Takuro Kojima, Noboru Iwata, Ahmed R. Ahmed, Khalid Dahy, Naoki Kondo, Kenji Suzuki   +11 more
doaj   +1 more source

Ligand-Activated Peroxisome Proliferator-Activated Receptor β/δ Facilitates Cell Proliferation in Human Cholesteatoma Keratinocytes

PPAR Research, 2020
Cholesteatoma is characterized by both the overgrowth of hyperkeratinized squamous epithelium and bone erosion. However, the exact mechanism underlying the hyperproliferative ability of cholesteatoma remains unknown. In this study, we investigated PPAR β/
Chen Zhang, Yang-Wenyi Liu, Zhangcai Chi, Bing Chen   +3 more
doaj   +1 more source

Management of Acquired Cholesteatoma Associated With Patulous Eustachian Tube and Habitual Sniffing [PDF]

Clinical and Experimental Otorhinolaryngology, 2019
Objectives To investigate the effect of surgical treatment with eustachian tube (ET) catheter insertion in patients with acquired cholesteatoma associated with patulous eustachian tube (PET) and habitual sniffing.
Sung-Won Choi, Dong-Joo Lee, Seok-Hwan Lee, Se-Joon Oh, Soo-Keun Kong   +4 more
doaj   +1 more source

Remodeling Factors, Transcription Factors and Angiogenetic Factors in Cholesteatoma in Ontogenetic Aspect [PDF]

Iranian Journal of Otorhinolaryngology, 2022
Introduction:The main goal of our study was to describe the transcription factor (NF-κβ), angiogenetic factor (VEGF), and remodeling markers (MMP-9 and TIMP-4) of the cholesteatoma tissue compared to control skin tissue. There are still uncertainties how
Kristaps Dambergs, Gunta Sumeraga, Māra Pilmane   +2 more
doaj   +1 more source

Expression of CYLD and NF-κB in Human Cholesteatoma Epithelium

Mediators of Inflammation, 2010
The tumor suppressor CYLD is a deubiquitinating enzyme that inhibits activation of the NF-κB, which has key roles in inflammation and apoptosis. We hypothesized that CYLD may regulate the NF-κB signaling pathway in cholesteatoma.
Jae Yong Byun, Tae Young Yune, Jee Youn Lee, Seung Geun Yeo, Moon Suh Park   +4 more
doaj   +1 more source

Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma.

PLoS ONE, 2020
Middle ear cholesteatoma is a destructive disease in which inflammation plays an important role in development and progression, and there are currently no biomarkers predicting prognosis or recurrence.
Shunsuke Miyake, Toru Miwa, Go Yoneda, Ayumi Kanemaru, Haruki Saito, Ryosei Minoda, Yorihisa Orita, Hideyuki Saito, Hirofumi Jono   +8 more
doaj   +1 more source